<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615602</url>
  </required_header>
  <id_info>
    <org_study_id>CT/04.23</org_study_id>
    <nct_id>NCT00615602</nct_id>
  </id_info>
  <brief_title>Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer</brief_title>
  <official_title>A Multicenter Randomized Phase III Study Comparing 6 Versus 12 Months of Trastuzumab in Combination With Dose Dense Docetaxel Following FE75C as Adjuvant Treatment of Women With Axillary Lymph Node Positive Breast Cancer Over-expressing HER2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare 6 versus 12 months of trastuzumab in combination with dose dense
      docetaxel following FE75C as adjuvant chemotherapy in women with axillary lymph node positive
      breast cancer overexpressing HER2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anthracycline-containing regimens are recommended as adjuvant treatment for women with node
      positive breast cancer. In at least three large randomized clinical trials the addition or
      sequential administration of a taxane (paclitaxel or docetaxel) to an antracycline-based
      regimen resulted in superior clinical outcome for women with node positive early breast
      cancer. In two large randomized studies the dose dense administration with G-CSF support of
      anthracycline-based and paclitaxel combination was superior to the same regimen administered
      every three weeks without growth factors as adjuvant therapy in women with axillary node
      positive breast cancer. In one randomized trial, docetaxel was proved superior to paclitaxel
      in women with metastatic breast cancer. Trastuzumab (anti-HER2 monoclonal antibody) in
      combination with paclitaxel was superior to paclitaxel alone in women with metastatic breast
      cancer overexpressing HER2
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>Relapses by the time of 3-years follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Τoxicity profile</measure>
    <time_frame>Toxicity assessment on each chemotherapy cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life between the two treatment arms</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">489</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FEC -&gt; TXT+H 12m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FEC -&gt; TXT+H 6m</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Farmorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluoruracil</intervention_name>
    <description>5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte-colony stimulating growth factor</intervention_name>
    <description>rhG-CSF 5 μg/kg/d on days 3-10 after each cycle</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Granocyte</other_name>
    <other_name>Neulasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histologically-confirmed unilateral invasive ductal or lobular breast
             adenocarcinoma

          -  HER2/c-neu over expression should be documented by either immunohistochemistry (score
             3+) or FISH/CISH positivity. A score of 2+ by immunohistochemistry is acceptable only
             if FISH/CISH positive

          -  Within 60 days after the surgical excision of the primary tumor with tumor-free
             operation margins; at least 10 axillary lymph nodes have to be removed.

          -  Tumor involvement of at least one axillary lymph node (N0 with HER2/c-neu over
             expression are also eligible)

          -  Absence of any clinical or radiological evidence of local or metastatic disease

          -  Premenopausal or postmenopausal women aged 18-75 years old

          -  Adequate bone marrow function (absolute neutrophil count &gt;1500/mm3, platelet count
             &gt;100.000/mm3, hemoglobin &gt;10gr/mm3)

          -  Adequate liver (bilirubin &lt;1.0 times upper limit of normal and SGOT/SGPT &lt;2.5 times
             upper limit of normal) and renal function (creatinine &lt;1.5mg/dl)

          -  Adequate cardiac function (LVEF&gt;50%). Normal electrocardiogram and absence of
             significant heart disease

          -  Written informed consent

        Exclusion Criteria:

          -  Positive pregnancy test.

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Prior or concurrent antineoplastic therapy e.g. hormonal therapy, radiation therapy,
             chemotherapy, biological agents.

          -  Previous history of other invasive malignancy other than non-melanomatous skin cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Mavrudis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Crete</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dep of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laikon&quot; General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Marika Iliadis&quot; Hospital of Athens, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State General Hospital of Larissa, Dep of Medical Oncology</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Theagenion&quot; Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early breast cancer</keyword>
  <keyword>Axillary node positive</keyword>
  <keyword>HER2 overexpression</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Dose dense</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>FEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

